arrow
A

Anastasia A. Aksyuk

AstraZeneca
H指数:16
被引数:1,519

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

High Conservation of the Human Metapneumovirus Fusion Protein in Contemporary Global Sequences Supports Its Continued Relevance for Therapeutic and Prophylactic Consideration

人类副黏病毒融合蛋白在当代全球序列中的高度保守性支持其持续作为治疗和预防考虑的重要性

2026-10-050
OA
A Phase IIa randomized clinical trial of a respiratory syncytial virus and human metapneumovirus combination protein-based virus-like particle vaccine in adults 60–85 years of age

一项针对60-85岁成年人呼吸道合胞病毒和人类偏肺病毒的重组蛋白病毒样颗粒组合疫苗的IIa期随机临床试验

Vaccine
IF3.5
2026-03-040
OAAI
A SARS-CoV-2 variant‑adjusted threshold of protection model for monoclonal antibody pre-exposure prophylaxis against COVID-19

针对COVID-19的单克隆抗体暴露前预防的保护阈值模型(SARS-CoV-2变体调整)

2025-10-140
OAAI
Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial

西帕韦伯特(sipavibart)预防免疫低下人群COVID-19的疗效与安全性(SUPERNOVA):一项随机、对照、双盲、III期试验

2025-02-010
PRE
Lower Respiratory Tract Infections Following Respiratory Syncytial Virus Monoclonal Antibody Nirsevimab Immunization Versus Placebo: Analysis From a Phase 3 Randomized Clinical Trial (MELODY)

呼吸道合胞病毒单克隆抗体Nirsevimab预防接种与安慰剂后的下呼吸道感染: 一项3期随机临床试验 (MELODY) 的分析

2024-12-041
OAAI
Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials (Vol 14, 4347, 2023)
2024-04-080
OAAI
Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials

两项nirsevimab随机临床试验中婴儿RSV感染的分子和表型特征

2023-07-1922
OAAI
Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data
2023-07-0135
PRE
Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants

PROVENT预防试验中的突破性SARS-CoV-2感染与AZD7442 (Tixagevimab/Cilgavimab) 耐药变体无关

2023-06-062
OAAI
Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults

半衰期延长的新型冠状病毒中和单克隆抗体AZD7442 (tixagevimab-cilgavimab) 在健康成人中的安全性,耐受性和药代动力学

2023-01-2312
OAAI
Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated
2023-01-139
OAAI